- Home
- VERI vs AGEN Comparison
VERI vs AGEN Comparison
Compare VERI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- AGEN
- Stock Information
- Founded
- VERI 2014
- AGEN 1994
- Country
- VERI United States
- AGEN United States
- Employees
- VERI N/A
- AGEN N/A
- Industry
- VERI EDP Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERI Technology
- AGEN Health Care
- Exchange
- VERI Nasdaq
- AGEN Nasdaq
- Market Cap
- VERI 91.5M
- AGEN 87.7M
- IPO Year
- VERI 2017
- AGEN 2000
- Fundamental
- Price
- VERI $1.25
- AGEN $4.59
- Analyst Decision
- VERI Strong Buy
- AGEN Buy
- Analyst Count
- VERI 3
- AGEN 4
- Target Price
- VERI $4.17
- AGEN $13.00
- AVG Volume (30 Days)
- VERI 1.1M
- AGEN 1.7M
- Earning Date
- VERI 08-07-2025
- AGEN 08-07-2025
- Dividend Yield
- VERI N/A
- AGEN N/A
- EPS Growth
- VERI N/A
- AGEN N/A
- EPS
- VERI N/A
- AGEN N/A
- Revenue
- VERI $90,947,000.00
- AGEN $99,524,000.00
- Revenue This Year
- VERI $15.84
- AGEN $12.69
- Revenue Next Year
- VERI $22.96
- AGEN N/A
- P/E Ratio
- VERI N/A
- AGEN N/A
- Revenue Growth
- VERI N/A
- AGEN N/A
- 52 Week Low
- VERI $1.22
- AGEN $1.38
- 52 Week High
- VERI $5.64
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- VERI 45.80
- AGEN 54.41
- Support Level
- VERI $1.50
- AGEN $4.71
- Resistance Level
- VERI $1.51
- AGEN $5.22
- Average True Range (ATR)
- VERI 0.12
- AGEN 0.36
- MACD
- VERI 0.01
- AGEN -0.09
- Stochastic Oscillator
- VERI 60.98
- AGEN 33.61
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).